Aliases & Classifications for Pulmonary Emphysema

MalaCards integrated aliases for Pulmonary Emphysema:

Name: Pulmonary Emphysema 38 12 55 44 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:9675
ICD10 33 J43.8
ICD9CM 35 492.8
MeSH 44 D011656

Summaries for Pulmonary Emphysema

MalaCards based summary : Pulmonary Emphysema is related to alpha-1-antitrypsin deficiency and bronchitis, and has symptoms including hemoptysis, snoring and coughing. An important gene associated with Pulmonary Emphysema is SERPINA1 (Serpin Family A Member 1), and among its related pathways/superpathways are Innate Immune System and Degradation of the extracellular matrix. The drugs Simvastatin and Doxycycline have been mentioned in the context of this disorder. Affiliated tissues include lung, bone and testes, and related phenotypes are homeostasis/metabolism and hematopoietic system

Related Diseases for Pulmonary Emphysema

Diseases in the Pulmonary Emphysema family:

Emphysema, Hereditary Pulmonary

Diseases related to Pulmonary Emphysema via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 140)
# Related Disease Score Top Affiliating Genes
1 alpha-1-antitrypsin deficiency 32.6 ELANE ELN SERPINA1
2 bronchitis 31.0 ELANE SERPINA1 SERPINB1
3 pneumothorax 30.2 ELN MMP1 MMP9 SERPINA1
4 vasculitis 30.1 ELANE SERPINA1 SERPINB1
5 pneumonia 30.0 ELANE SFTPC SFTPD
6 bronchiectasis 29.9 ELANE MMP8 SERPINA1
7 granulomatosis with polyangiitis 29.8 ELANE SERPINA1 SERPINB1
8 pulmonary fibrosis 29.8 MMP9 SFTPC SFTPD TIMP1
9 bacterial pneumonia 29.8 ELANE ELN SFTPD
10 conjunctivochalasis 29.7 MMP1 TIMP1 TIMP2
11 diffuse pulmonary fibrosis 29.7 SERPINA1 SFTPC TIMP1
12 interstitial lung disease 29.4 MMP9 SFTPC SFTPD TIMP1
13 idiopathic interstitial pneumonia 29.4 ELANE SFTPC SFTPD
14 respiratory failure 29.3 ELANE SERPINA1 SFTPC SFTPD
15 pulmonary disease, chronic obstructive 29.1 ELANE ELN HMOX1 MMP1 MMP12 MMP9
16 periodontal disease 29.1 ELANE MMP1 MMP8 MMP9 TIMP1 TIMP2
17 pulmonary fibrosis, idiopathic 28.9 ELANE MMP1 MMP9 SFTPC SFTPD TIMP1
18 lung disease 28.6 ELANE ELN HMOX1 MMP8 MMP9 SERPINA1
19 berry aneurysm, cirrhosis, pulmonary emphysema, and cerebral calcification 12.3
20 autosomal recessive cutis laxa type i 11.9
21 asthma 10.3
22 lung cancer 10.3
23 cerebral aneurysms 10.2 ELANE ELN
24 senile ectropion 10.2 ELN MMP9
25 elephantiasis 10.2 ELANE ELN
26 spastic entropion 10.2 MMP1 MMP9
27 gingival hypertrophy 10.2 MMP9 TIMP2
28 internal hemorrhoid 10.2 MMP1 MMP9
29 impetigo herpetiformis 10.2 ELANE SERPINB1
30 chromoblastomycosis 10.2 MMP1 MMP9
31 autoimmune inner ear disease 10.2 MMP9 TIMP1
32 adult astrocytic tumour 10.2 MMP1 MMP9
33 plasma protein metabolism disease 10.2 ELANE SERPINA1
34 periodontosis 10.2 ELANE MMP9
35 chronic actinic dermatitis 10.2 ELN MMP1 MMP9
36 cryptogenic organizing pneumonia 10.2 MMP9 TIMP1
37 conjunctival nevus 10.2 MMP9 TIMP1
38 cutis laxa 10.1
39 lipodermatosclerosis 10.1 MMP1 TIMP2
40 aortic aneurysm, familial thoracic 1 10.1 ELN MMP1 MMP9
41 microcystic meningioma 10.1 TIMP1 TIMP2
42 central nervous system tuberculosis 10.1 ELANE MMP9 TIMP1
43 odontogenic myxoma 10.1 MMP1 MMP9
44 endodermal sinus tumor 10.1 SERPINA1 TIMP1
45 marfan syndrome 10.1
46 myocardial infarction 10.1
47 pulmonary hypertension 10.1
48 peptic ulcer disease 10.1
49 amaurosis fugax 10.1 MMP8 MMP9
50 kawasaki disease 10.1 ELANE MMP9 TIMP1

Comorbidity relations with Pulmonary Emphysema via Phenotypic Disease Network (PDN):


Heart Disease

Graphical network of the top 20 diseases related to Pulmonary Emphysema:



Diseases related to Pulmonary Emphysema

Symptoms & Phenotypes for Pulmonary Emphysema

UMLS symptoms related to Pulmonary Emphysema:


hemoptysis, snoring, coughing

MGI Mouse Phenotypes related to Pulmonary Emphysema:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10 ELANE HMOX1 MMP1 MMP12 MMP8 MMP9
2 hematopoietic system MP:0005397 9.92 ELANE HMOX1 MMP12 MMP9 SERPINB1 SFTPD
3 immune system MP:0005387 9.9 ELANE HMOX1 MMP1 MMP12 MMP8 MMP9
4 neoplasm MP:0002006 9.43 ELANE MMP1 MMP8 MMP9 SFTPC TIMP1
5 respiratory system MP:0005388 9.23 HMOX1 MMP12 MMP9 SERPINB1 SESN2 SFTPC

Drugs & Therapeutics for Pulmonary Emphysema

Drugs for Pulmonary Emphysema (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 290)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4 79902-63-9 54454
2
Doxycycline Approved, Investigational, Vet_approved Phase 4,Not Applicable 564-25-0 54671203
3
Budesonide Approved Phase 4,Phase 3 51333-22-3 63006 5281004
4
Fluticasone Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 90566-53-3 62924
5
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 1 302-25-0
6
Methylprednisolone Approved, Vet_approved Phase 4,Phase 1 83-43-2 6741
7
Methylprednisolone hemisuccinate Approved Phase 4,Phase 1 2921-57-5
8
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
9
Prednisolone Approved, Vet_approved Phase 4,Phase 1 50-24-8 5755
10
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
11
Losartan Approved Phase 4 114798-26-4 3961
12
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3 50-02-2 5743
13
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3 1177-87-3
14
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
15
Serine Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 56-45-1 5951
16
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 77-92-9 311
17
Prednisolone hemisuccinate Experimental Phase 4,Phase 1 2920-86-7
18
Lactitol Investigational Phase 4 585-86-4 3871
19 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Hypolipidemic Agents Phase 4,Phase 1
21 Anticholesteremic Agents Phase 4
22 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
23 Antimetabolites Phase 4,Phase 1,Not Applicable
24 Lipid Regulating Agents Phase 4,Phase 1
25 Tiotropium Bromide Phase 4,Phase 2 136310-93-5
26 Adrenergic beta-Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
29 Formoterol Fumarate Phase 4,Phase 3,Phase 2
30 Cholinergic Antagonists Phase 4,Phase 2
31 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Bronchodilator Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
34 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Cholinergic Agents Phase 4,Phase 2,Not Applicable
36 Parasympatholytics Phase 4,Phase 2
37 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 glucocorticoids Phase 4,Phase 3,Phase 1,Not Applicable
39 Adrenergic Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41
Beclomethasone Phase 4,Phase 3,Not Applicable 4419-39-0 20469
42 Respiratory System Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
43 Bromides Phase 4,Phase 3,Phase 2
44 Adrenergic beta-2 Receptor Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Antiparasitic Agents Phase 4,Not Applicable
48 Antiprotozoal Agents Phase 4,Not Applicable
49 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Not Applicable
50 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 552)
# Name Status NCT ID Phase Drugs
1 AeriSeal System in Patients With Advanced Upper Lobe Predominant Emphysema and Collateral Ventilation Unknown status NCT01460108 Phase 4
2 EUROPT Clinical Trial to Study the Efficacy of One-Way Valve Implantation (New Treatment Algorithm) in Patients With Heterogeneous Emphysema Unknown status NCT00730301 Phase 4
3 Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Obstructive Chronic Pulmonary Disease (COPD) Phenotype Unknown status NCT01431625 Phase 4
4 Simvastatin in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT00680641 Phase 4 Simvastatin;Placebo
5 Evaluate the Effects of Formoterol and Beclomethasone Dipropionate Combination Therapy on Small Airways Function Unknown status NCT01466712 Phase 4 Tiotropium + formoterol/beclometasone;tiotropium + placebo
6 Doxycycline and Airway Inflammation in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT00857038 Phase 4 Doxycycline;Placebo
7 Surfactant Administration During Spontaneous Breathing Unknown status NCT01329432 Phase 4
8 Sunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed Tomography Unknown status NCT01361984 Phase 4 Nebulized arformoterol;Salmeterol
9 Small Airways Evaluation and Treatment Unknown status NCT02526758 Phase 4 beclomethasone;formoterol;budesonide
10 Cpap at Delivery Room for Preterm Infants Unknown status NCT01024361 Phase 4
11 Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency Completed NCT00261833 Phase 4
12 Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency. Completed NCT00670007 Phase 4
13 Hypoxic Pulmonary Vasoconstriction Pilot Study Completed NCT03733470 Phase 4 Hypoxia Administration study group;Hyperoxia Administration study group;Sildenafil study group
14 Efficacy of Losartan in Preventing Progression of COPD Completed NCT00720226 Phase 4 Losartan;Placebo
15 Efficacy Study of the Effect of Budesonide on Emphysema Completed NCT00232674 Phase 4 Pulmicort (budesonide) Turbuhaler
16 Effectiveness of Different Exercise Training Programs to the Profile of COPD Patients Completed NCT01336283 Phase 4
17 Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD) Completed NCT00424528 Phase 4 Arformoterol Tartrate Inhalation Solution;Tiotropium;Arformoterol and Tiotropium;Placebo
18 Add-on Effects of Tiotropium Over Formoterol in Exercise Tolerance on Chronic Obstructive Pulmonary Disease Patients Completed NCT00680056 Phase 4 Formoterol plus Placebo (Tiotropium);Formoterol plus Tiotropium
19 Dynamic Hyperinflation and Tiotropium Completed NCT00569270 Phase 4 tiotropium;placebo;tiotropium
20 The Effectiveness of Roflumilast in Improving Mucociliary Clearance in Patients With COPD and Chronic Bronchitis Completed NCT03073798 Phase 4 Roflumilast;Placebo
21 Airway Clearance for Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Completed NCT00181207 Phase 4
22 Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study Completed NCT01110200 Phase 4 ADVAIR DISKUS 250/50 mg BID;SEREVENT 50 mcg BID
23 Inhaled Steroid Reduces Systemic Inflammation in COPD Completed NCT00175565 Phase 4 inhaled fluticasone 500 mcg b.i.d.
24 Change of Inspiratory Peak Flow in COPD Completed NCT00561886 Phase 4 Formoterol
25 Acute Effect of Aclidinium on Hyperinflation and Ventilation Inhomogeneity in Severe COPD Patients Completed NCT02181023 Phase 4 Aclidinium Bromide;Glycopyrronium Bromide
26 Acute Effect of Pulmonary Desufflation on Cardiac Performance in COPD Patients Completed NCT01996124 Phase 4 Indacaterol Fumarate;Placebo
27 An Investigation of the Mechanism of Action of Seretide in Chronic Obstructive Pulmonary Disease Completed NCT00974805 Phase 4 Seretide 500 Accuhaler
28 Efficacy Safety Study of Arformoterol QD Dosing Versus BID Dosing in COPD Completed NCT00571428 Phase 4 Arformoterol Tartrate Inhalation Solution;Arformoterol Tartrate Inhalation Solution;Placebo
29 Roflumilast on Markers of Bone Metabolism and Endothelial Function in COPD Completed NCT01745848 Phase 4 Roflumilast
30 A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Completed NCT00857766 Phase 4 ADVAIR DISKUS™ 250/50mcg
31 Effects of Inhaled Corticosteroids in the Systemic Inflammation Induced by Exercise in Patients With COPD Completed NCT02209974 Phase 4 Fluticasone;Inhaled Placebo
32 Nebulized 3% Hypertonic Saline Solution Treatment of Bronchiolitis in Infants Completed NCT02233985 Phase 4 0.9% Sodium Chloride;3% Sodium Chloride
33 Costs & Outcomes of Hospitalization/Treatment With Levalbuterol & Albuterol in Asthma or Chronic Obstructive Pulmonary Disease (COPD) Subjects Completed NCT00667797 Phase 4 levalbuterol HCl;albuterol Sulfate
34 Study of the Effect of the ROX AC1 on Exercise Capacity and Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients Completed NCT00832611 Phase 4
35 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy Completed NCT01959711 Phase 4
36 Altitude Related Illness In Patients With Respiratory Disease Completed NCT02450968 Phase 4 Dexamethasone;Placebo
37 Indacaterol Versus Tiotropium on Dynamic Hyperinflation in COPD Completed NCT01693003 Phase 4 Indacaterol;Tiotropium
38 Effect of Dexamethasone on Sleep Related Breathing Disturbances in Patients With COPD at Altitude Completed NCT02450994 Phase 4 Dexamethasone;Placebo
39 Effects of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease (COPD) Completed NCT00202189 Phase 4 Budesonide
40 GLASSIA Infusion Rate Study Completed NCT01651351 Phase 4
41 Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor) Completed NCT00396006 Phase 4
42 Losartan Effects on Emphysema Progression Recruiting NCT02696564 Phase 4 Losartan;Placebo
43 Functional CT Assessment of Pulmonary Arterial Dysfunction in Smoking Associated Emphysema Recruiting NCT02682147 Phase 4 Hypoxia administration study group;Hyperoxia administration study group;Sildenafil
44 Smoking Cessation and Functional CT Assessment Recruiting NCT03382106 Phase 4 Sildenafil 20 MG;Placebo Oral Tablet
45 RELVAR Effects on Parasternal Muscle Activity, Diaphragm, and Ventilation in Severe COPD Recruiting NCT02989935 Phase 4
46 Patients With Chronic Obstructive Pulmonary Disease at Altitude - Effect of Nocturnal Oxygen on Breathing and Sleep Recruiting NCT02150590 Phase 4 Oxygen;sham oxygen (room air)
47 Dose of Corticosteroids in COPD Recruiting NCT01742338 Phase 4 Low Dose Corticosteroids;High Dose Corticosteroids
48 Effect Of Acetazolamide On Altitude Related Illness In Patients With Respiratory Disease Recruiting NCT03156231 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
49 Effect of Acetazolamide on Right Ventricular Function at Rest in Patients With Respiratory Disease at Altitude Recruiting NCT03173508 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
50 Effect of Acetazolamide on Sleep Related Breathing Disturbances in Patients With Respiratory Disease at Altitude Recruiting NCT03177850 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule

Search NIH Clinical Center for Pulmonary Emphysema

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Pulmonary Emphysema cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: pulmonary emphysema

Genetic Tests for Pulmonary Emphysema

Anatomical Context for Pulmonary Emphysema

MalaCards organs/tissues related to Pulmonary Emphysema:

41
Lung, Bone, Testes, Neutrophil, Heart, Liver, Skin

Publications for Pulmonary Emphysema

Articles related to Pulmonary Emphysema:

(show top 50) (show all 1014)
# Title Authors Year
1
To investigate dose reduction and comparability of standard dose CT vs Ultra low dose CT in evaluating pulmonary emphysema. ( 30340073 )
2019
2
Progression of Pulmonary Emphysema and Continued Increase in Ectodomain Shedding of Cell Adhesion Molecule 1 After Cessation of Cigarette Smoke Exposure in Mice. ( 29892598 )
2018
3
Pulmonary Emphysema Quantification on Ultra-Low-Dose Computed Tomography Using Model-Based Iterative Reconstruction With or Without Lung Setting. ( 29958197 )
2018
4
MMP-12 activates protease activated receptor (PAR)-1, upregulates placenta growth factor and leads to pulmonary emphysema. ( 29722565 )
2018
5
Perception and Awareness of chronic obstructive pulmonary disease, Chronic Bronchitis and Pulmonary Emphysema in the Spanish Urban Population. ( 29428681 )
2018
6
Heterogeneity in pulmonary emphysema: Analysis of CT attenuation using Gaussian mixture model. ( 29444178 )
2018
7
Quantitative and Qualitative Assessment of Pulmonary Emphysema with T2-Weighted PROPELLER MRI in a High-Risk Population Compared to Low-Dose CT. ( 29514383 )
2018
8
An Additional Treatment Option for One-Sided Pulmonary Emphysema - A Case Report. ( 29895080 )
2018
9
Severe pulmonary emphysema in a young patient with vasculitis associated with proteinase-3 anti-neutrophil cytoplasmic antibodies (PR3-ANCA). ( 29357994 )
2018
10
Bone Marrow-Derived Mononuclear Cell Therapy in Papain-Induced Experimental Pulmonary Emphysema. ( 29515461 )
2018
11
Alpha-1 antitrypsin deficiency as a common treatable mechanism in chronic respiratory disorders and for conditions different from pulmonary emphysema? A commentary on the new European Respiratory Society statement. ( 30338069 )
2018
12
Right Hemothorax Caused by Septal Puncture During Catheter Ablation for Atrial Fibrillation: A Case With Atrial Septal Aneurysm and Pulmonary Emphysema. ( 30067498 )
2018
13
Quantitative severity of pulmonary emphysema as a prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. ( 30507005 )
2018
14
Systemic bone loss, impaired osteogenic activity and type I muscle fiber atrophy in mice with elastase-induced pulmonary emphysema: Establishment of a COPD-related osteoporosis mouse model. ( 30342225 )
2018
15
Elimination of p19ARF -expressing cells protects against pulmonary emphysema in mice. ( 30058137 )
2018
16
Sphingosine 1-phosphate receptor modulator ONO-4641 stimulates CD11b+Gr-1+ cell expansion and inhibits lymphocyte infiltration in the lungs to ameliorate murine pulmonary emphysema. ( 30116000 )
2018
17
Successful lung volume reduction surgery in combined pulmonary emphysema and fibrosis without body-plethysmographic hyperinflation-a case report. ( 30210838 )
2018
18
Impact of pulmonary emphysema on exercise capacity and its physiological determinants in chronic obstructive pulmonary disease. ( 30356114 )
2018
19
T2-weighted PROPELLER MRI is not suitable for pulmonary emphysema quantification. ( 30360005 )
2018
20
Response to "T2-weighted PROPELLER MRI is not suitable for pulmonary emphysema quantification". ( 30360006 )
2018
21
Role of Stem Cells in the Pathogenesis of Chronic Obstructive Pulmonary Disease and Pulmonary Emphysema. ( 30468084 )
2018
22
Endothelial Progenitor Cells and Notch-1 Signaling as Markers of Alveolar Endothelium Regeneration in Pulmonary Emphysema. ( 30488216 )
2018
23
Dietary Nitrite Attenuates Elastase-Induced Pulmonary Emphysema in a Mouse Model. ( 30504683 )
2018
24
Pulmonary emphysema is a risk factor for radiation pneumonitis in NSCLC patients with squamous cell carcinoma after thoracic radiation therapy. ( 28584268 )
2017
25
Pulmonary Emphysema Cross-Linking with Pulmonary Fibrosis and Vice Versa: a Non-usual Experimental Intervention with Elastase and Bleomycin. ( 28534139 )
2017
26
Bacteriological incidence in pneumonia patients with pulmonary emphysema: a bacterial floral analysis using the 16S ribosomal RNA gene in bronchoalveolar lavage fluid. ( 28790814 )
2017
27
Frequency of Epidermal Growth Factor Receptor Mutation in Smokers with Lung Cancer Without Pulmonary Emphysema. ( 28179328 )
2017
28
A Low Peripheral Blood CD4/CD8 Ratio Is Associated with Pulmonary Emphysema in HIV. ( 28122034 )
2017
29
Combined Bone Marrow-Derived Mesenchymal Stromal Cell Therapy and One-Way Endobronchial Valve Placement in Patients with Pulmonary Emphysema: A Phase I Clinical Trial. ( 28186686 )
2017
30
AMP-activated protein kinase reduces inflammatory responses and cellular senescence in pulmonary emphysema. ( 28186975 )
2017
31
The copper dependent-lysyl oxidases contribute to the pathogenesis of pulmonary emphysema in chronic obstructive pulmonary disease patients. ( 28965583 )
2017
32
Improvement of metabolic disorders by an EP(2) receptor agonist via restoration of the subcutaneous adipose tissue in pulmonary emphysema. ( 28263859 )
2017
33
Hydrogen-rich pure water prevents cigarette smoke-induced pulmonary emphysema in SMP30 knockout mice. ( 28807355 )
2017
34
Lipidomes of lung cancer and tumour-free lung tissues reveal distinct molecular signatures for cancer differentiation, age, inflammation, and pulmonary emphysema. ( 28894173 )
2017
35
Mild pulmonary emphysema a risk factor for interstitial lung disease when using cetuximab for squamous cell carcinoma of the head and neck. ( 28741444 )
2017
36
Prognostic Value of Radiation Pneumonitis After Stereotactic Body Radiotherapy: Effect of Pulmonary Emphysema Quantitated Using CTA Images. ( 28655592 )
2017
37
Images in COPD: Combined Pulmonary Emphysema and Fibrosis with Pulmonary Hypertension. ( 28848914 )
2017
38
Pulmonary emphysema is a predictor of pneumothorax after CT-guided transthoracic pulmonary biopsies of pulmonary nodules. ( 28574995 )
2017
39
Unsupervised Discovery of Spatially-Informed Lung Texture Patterns for Pulmonary Emphysema: The MESA COPD Study. ( 29354811 )
2017
40
Effect of arginine vasopressin on systemic and pulmonary arterial pressure in a patient with pulmonary hypertension secondary to pulmonary emphysema: a case report. ( 29492440 )
2017
41
Pulmonary Rehabilitation Improves Exercise Capacity And Molecular Skeletal Muscle Adaptation In Pulmonary Emphysema Patients: 2972 Board #37 June 3, 3: 30 PM - 5: 00 PM. ( 27361541 )
2016
42
Lung regeneration by fetal lung tissue implantation in a mouse pulmonary emphysema model. ( 27644555 )
2016
43
Acute pulmonary emphysema in death by hanging: a morphometric digital study. ( 27448112 )
2016
44
Lung volume reduction of pulmonary emphysema: the radiologist task. ( 26807689 )
2016
45
Comparison of Serum Adiponectin in Smoke-induced Pulmonary Emphysema Rats Fed Different Diets. ( 26830990 )
2016
46
Development of digital phantoms based on a finite element model to simulate low-attenuation areas in CT imaging for pulmonary emphysema quantification. ( 27838881 )
2016
47
Determinants of exercise-induced oxygen desaturation including pulmonary emphysema in COPD: Results from the ECLIPSE study. ( 27692154 )
2016
48
Ascorbate attenuates pulmonary emphysema by inhibiting tobacco smoke and Rtp801-triggered lung protein modification and proteolysis. ( 27382160 )
2016
49
Critical role of tumor necrosis factor receptor 1 in the pathogenesis of pulmonary emphysema in mice. ( 27555760 )
2016
50
Smoking-related interstitial fibrosis combined with pulmonary emphysema: computed tomography-pathologic correlative study using lobectomy specimens. ( 27445472 )
2016

Variations for Pulmonary Emphysema

Expression for Pulmonary Emphysema

LifeMap Discovery
Genes differentially expressed in tissues of Pulmonary Emphysema patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 S100A12 S100 calcium binding protein A12 Lung - 3.38 0.026
2 SERPIND1 serpin peptidase inhibitor, clade D (heparin cofactor), member 1 Lung + 3.23 0.020
3 HLA-DOA major histocompatibility complex, class II, DO alpha Lung + 3.20 0.002
Search GEO for disease gene expression data for Pulmonary Emphysema.

Pathways for Pulmonary Emphysema

Pathways related to Pulmonary Emphysema according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.76 ELANE HMOX1 MMP1 MMP8 MMP9 SERPINA1
2
Show member pathways
12.51 ELANE ELN MMP1 MMP12 MMP8 MMP9
3
Show member pathways
11.98 ELN MMP1 MMP12 MMP8 MMP9
4 11.95 MMP1 MMP12 MMP9
5 11.79 HMOX1 MMP1 MMP9 TIMP1
6 11.62 HMOX1 MMP9 TIMP1 TIMP2
7 11.5 MMP1 MMP12 MMP9 TIMP1 TIMP2
8 11.23 ELN HMOX1 MMP9 SERPINA1 SFTPC TIMP1
9 11.16 HMOX1 MMP1 MMP9
10
Show member pathways
11.16 ELANE MMP1 MMP12 MMP8 MMP9 TIMP1
11 11.14 ELANE ELN MMP1 MMP9 TIMP2
12 10.98 MMP9 TIMP1 TIMP2
13
Show member pathways
10.95 SFTPC SFTPD
14 10.92 MMP9 TIMP2
15 10.8 MMP1 TIMP1
16 10.73 MMP1 MMP9

GO Terms for Pulmonary Emphysema

Cellular components related to Pulmonary Emphysema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.9 ELANE HMOX1 MMP12 MMP8 MMP9 SERPINA1
2 extracellular matrix GO:0031012 9.8 ELN MMP1 MMP12 MMP8 MMP9 TIMP1
3 ficolin-1-rich granule lumen GO:1904813 9.58 MMP9 SERPINA1 TIMP2
4 specific granule lumen GO:0035580 9.54 ELANE MMP8 TIMP2
5 tertiary granule lumen GO:1904724 9.5 MMP8 MMP9 TIMP2
6 collagen-containing extracellular matrix GO:0062023 9.5 ELANE ELN MMP8 MMP9 SERPINA1 SERPINB1
7 clathrin-coated endocytic vesicle GO:0045334 9.43 SFTPC SFTPD
8 extracellular region GO:0005576 9.4 ELANE ELN MMP1 MMP12 MMP8 MMP9

Biological processes related to Pulmonary Emphysema according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 proteolysis GO:0006508 9.91 ELANE MMP1 MMP12 MMP8 MMP9
2 cytokine-mediated signaling pathway GO:0019221 9.8 HMOX1 MMP1 MMP9 TIMP1
3 leukocyte migration GO:0050900 9.73 ELANE MMP1 MMP9
4 neutrophil degranulation GO:0043312 9.73 ELANE MMP8 MMP9 SERPINA1 SERPINB1 TIMP2
5 negative regulation of endopeptidase activity GO:0010951 9.67 SERPINA1 SERPINB1 TIMP1 TIMP2
6 negative regulation of peptidase activity GO:0010466 9.62 SERPINA1 SERPINB1 TIMP1 TIMP2
7 respiratory gaseous exchange GO:0007585 9.58 ELN SFTPC SFTPD
8 positive regulation of macroautophagy GO:0016239 9.55 HMOX1 SESN2
9 cellular protein metabolic process GO:0044267 9.55 MMP1 SERPINA1 SFTPC SFTPD TIMP1
10 positive regulation of DNA binding GO:0043388 9.54 MMP8 MMP9
11 endodermal cell differentiation GO:0035987 9.52 MMP8 MMP9
12 negative regulation of membrane protein ectodomain proteolysis GO:0051045 9.48 TIMP1 TIMP2
13 regulation of neuroinflammatory response GO:0150077 9.46 MMP8 MMP9
14 negative regulation of metallopeptidase activity GO:1905049 9.43 TIMP1 TIMP2
15 collagen catabolic process GO:0030574 9.26 MMP1 MMP12 MMP8 MMP9
16 extracellular matrix disassembly GO:0022617 9.17 ELANE MMP1 MMP12 MMP8 MMP9 TIMP1

Molecular functions related to Pulmonary Emphysema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.88 MMP1 MMP12 MMP8 MMP9 TIMP1 TIMP2
2 peptidase activity GO:0008233 9.83 ELANE MMP1 MMP12 MMP8 MMP9
3 metallopeptidase activity GO:0008237 9.67 MMP1 MMP12 MMP8 MMP9
4 peptidase inhibitor activity GO:0030414 9.62 SERPINA1 SERPINB1 TIMP1 TIMP2
5 metalloendopeptidase activity GO:0004222 9.56 MMP1 MMP12 MMP8 MMP9
6 metalloendopeptidase inhibitor activity GO:0008191 9.46 TIMP1 TIMP2
7 protease binding GO:0002020 9.46 ELANE SERPINA1 TIMP1 TIMP2
8 serine-type endopeptidase activity GO:0004252 9.35 ELANE MMP1 MMP12 MMP8 MMP9
9 endopeptidase activity GO:0004175 9.02 ELANE MMP1 MMP12 MMP8 MMP9

Sources for Pulmonary Emphysema

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....